Roles of connective tissue growth factor and prostanoids in early streptozotocin-induced diabetic rat kidney: The effect of aspirin treatment

Clinical and Experimental Nephrology

Volumn 7, Issue 1, 2003, Pages 33-40

  Makino, Hisashi ^a   Mukoyama, Masashi ^a   Sugawara, Akira ^a   Mori, Kiyoshi ^a   Suganami, Takayoshi ^a   Yahata, Kensei ^a   Fujinaga, Yuriko ^a   Yokoi, Hideki ^a   Tanaka, Issei ^a   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Connective tissue growth factor; Cyclooxygenase inhibitor; Diabetic nephropathy; Extracellular matrix; Prostanoids; Transforming growth factor

Indexed keywords

ACETYLSALICYLIC ACID; CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE; FIBRONECTIN; GLUCOSE; PROSTAGLANDIN SYNTHASE; PROSTANOID; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; EXTRACELLULAR MATRIX; GENE CONTROL; GENE EXPRESSION; HISTOLOGY; LONG TERM CARE; MALE; MESANGIUM CELL; NONHUMAN; NORTHERN BLOTTING; RAT; UPREGULATION;

ANIMALS; ASPIRIN; BLOTTING, NORTHERN; CELLS, CULTURED; CYCLOOXYGENASE INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBRONECTINS; GENE EXPRESSION REGULATION; GLOMERULAR MESANGIUM; GLUCOSE; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY GLOMERULUS; KINETICS; MALE; PROSTAGLANDINS; RATS; RATS, WISTAR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0037362456     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101570300004     Document Type: Article

References (40)

1. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-33.
2. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;74:1143-55.
3. Ziyadeh FN. The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993;22:736-44.
4. Park IS, Kiyomoto H, Abboud SL, Abboud HE. Expression of transforming growth factor-β and type IV collagen in early streptozotocin-induced diabetes. Diabetes 1997;46:473-80.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
6. Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer SM. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998;339:69-75.
7. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-8.
8. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney Int 1992;42:647-56.
9. Roberts AB, McCune BK, Sporn MB. TGF-β: regulation of extracellular matrix. Kidney Int 1992;41:557-9.
10. Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991;114:1285-94.
11. Ryseck RP, Macdonald-Bravo H, Mattei MG, Bravo R. Structure, mapping, and expression of fisp-12, a growth factor-inducible Mattei gene encoding a secreted cysteine-rich protein. Cell Growth Differ 1991;2:225-33.
12. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993;327:125-30.
13. Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 1993;4:637-45.
14. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996;105:404-11.
15. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998;53:853-61.
16. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999;274:5830-4.
17. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000;11:25-38.
18. Gupta S, Clarkson MR, Duggan J, Brady HR. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000;58:1389-99.
19. Yokoi H, Sugawara A, Mukoyama M, Mori K, Makino H, Suganami T, et al. Role of connective tissue growth factor in profibrotic action of transforming growth factor-β: a potential target for preventing renal fibrosis. Am J Kidney Dis 2001;38:S134-8.
20. Ricupero DA, Rishikof DC, Kuang PP, Poliks CF, Goldstein RH. Regulation of connective tissue growth factor expression by prostaglandin E2. Am J Physiol 1999;275:L1165-71.
21. DeRubertis FR, Craven PA. Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes. Am J Kidney Dis 1993;22:727-35.
22. Schambelan M, Blake S, Sraer J, Bens M, Nivez MP, Wahbe F. Increased prostaglandin production by glomeruli isolated from rats with streptozotocin-induced diabetes mellitus. J Clin Invest 1985;75:404-12.
23. Craven PA, DeRubertis FR. Role of local prostaglandin and thromboxane production in the regulation of glomerular filtration rate in the rat with streptozotocin-induced diabetes. J Lab Clin Med 1989;113:674-81.
24. Moel DI, Safirstein RL, McEvoy RC, Hsueh W. Effect of aspirin on experimental diabetic nephropathy. J Lab Clin Med 1987;110:300-7.
25. Hommel E, Mathiesen E, Arnold-Larsen S, Edsberg B, Olsen UB, Parving HH. Effects of indomethacin on kidney function in type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia 1987;30:78-81.
26. Suganami T, Mukoyama M, Sugawara A, Mori K, Nagae T, Kasahara M, et al. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J Am Soc Nephrol 2001;12:2652-63.
27. Ishibashi R, Tanaka I, Kotani M, Muro S. Goto M, Sugawara A, et al. Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Kidney Int 1999;56:589-600.
28. Shankland SJ, Scholey JW, Ly H, Thai K. Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int 1994;46:430-42.
29. Schwarzbauer JE. Patel RS, Fonda D, Hynes RO. Multiple sites of alternative splicing of the rat fibronectin gene transcript. EMBO J 1987;6:2573-80.
30. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45:522-30.
31. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-de la Cruz MC, Hong SW, Isono M, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015-20.
32. Isaka Y, Akagi Y, Ando Y, Imai E. Application of gene therapy to diabetic nephropathy. Kidney Int 1997;60:S100-3.
33. Schull MM. Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992; 359:693-9.
34. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, et al. Connective tissue growth factor mediates transforming growth factor β-induced collagen synthesis: downregulation by cAMP. FASEB J 1999;13:1774-86.
35. Zhang SY, Suzuki D, Umezono T, Toyoda M, Sakai H. Expression of connective tissue growth factor mRNA in human IgA nephropathy. Clin Exp Nephrol 2001;5:33-9.
36. Dammeier J, Beer HD, Brauchle M, Werner S. Dexamethasone is a novel potent inducer of connective tissue growth factor expression: implications for glucocorticoid therapy. J Biol Chem 1998;273:18185-90.
37. Mahadevan P, Larkins RG, Fraser JR, Dunlop ME. Effect of prostaglandin E2 and hyaluronan on mesangial cell proliferation: a potential contribution to glomerular hypercellularity in diabetes. Diabetes 1996;45:44-50.
38. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997;100:115-26.
39. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996;272:728-31.
40. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S. et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000;14:439-47.